Vafseo(vadadustat)
Vafseo (vadadustat) is a small molecule pharmaceutical. Vadadustat was first approved as Vafseo on 2023-04-24. It is used to treat anemia in the USA. It has been approved in Europe to treat anemia and chronic renal insufficiency. It is known to target egl nine homolog 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Vafseo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vadadustat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VAFSEO | Akebia Therapeutics | N-215192 RX | 2024-03-27 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vafseo | New Drug Application | 2024-06-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| anemia | HP_0001903 | D000740 | D64.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | HP_0001903 | D64.9 | 1 | 8 | 14 | — | — | 23 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 9 | 13 | — | — | 23 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 8 | 13 | — | — | 22 |
| Healthy volunteers/patients | — | — | — | 7 | — | 1 | — | — | 8 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | — | 1 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | — | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vadadustat |
| INN | vadadustat |
| Description | Vadadustat, sold under the brand name Vafseo, is a medication used for the treatment of symptomatic anemia associated with chronic kidney disease.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O |
Identifiers
| PDB | — |
| CAS-ID | 1000025-07-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3646221 |
| ChEBI ID | — |
| PubChem CID | 23634441 |
| DrugBank | DB12255 |
| UNII ID | I60W9520VV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
EGLN1
EGLN1
Organism
Homo sapiens
Gene name
EGLN1
Gene synonyms
C1orf12
NCBI Gene ID
Protein name
egl nine homolog 1
Protein synonyms
egl nine-like protein 1, HIF-PH2, HIF-prolyl hydroxylase 2, HPH-2, Hypoxia-inducible factor prolyl hydroxylase 2, PHD2, Prolyl hydroxylase domain-containing protein 2, SM-20, zinc finger MYND domain-containing protein 6
Uniprot ID
Mouse ortholog
Egln1 (112405)
egl nine homolog 1 (Q922P3)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 485 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vafseo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use